Floatz logo

Therapeutic Asset Ratings

5,098 results matching 1 filter

91,565 assets7,904 sponsors3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
Abemaciclib
Urinary System Neoplasm
Eli Lilly and CompanyP3B (60)
Abiraterone
Chemotherapy-Induced Toxicity
Eli Lilly and CompanyP3B (60)
Abiraterone
Melanoma, Cutaneous Malignant, Susceptibility To, 3
Eli Lilly and CompanyP3B (60)
Abiraterone
Microcephaly 12, Primary, Autosomal Recessive
Eli Lilly and CompanyP3B (60)
Abiraterone
Differentiated Thyroid Carcinoma
ExelixisP3B (60)
Abiraterone
Pancreatic Neuroendocrine Tumor
ExelixisP3B (60)
Abiraterone
Renal Cell Carcinoma
ExelixisP3B (60)
Abiraterone
Urinary System Neoplasm
Eli Lilly and CompanyP3B (60)
Abp 234
Non-Small Cell Lung Carcinoma
AmgenP3B (60)
Abp 692
Relapsing-Remitting Multiple Sclerosis
AmgenP3B (60)
Acetylcysteine
Beta Thalassemia
Tanta UniversityP3B (60)
Acoramidis
Hereditary Amyloidosis
Eidos Therapeutics, a BridgeBio companyP3B (60)
Acoramidis
Familial Amyloid Neuropathy
Eidos Therapeutics, a BridgeBio companyP3B (60)
Acoramidis
Cardiovascular Disorder
Eidos Therapeutics, a BridgeBio companyP3B (60)
Acoramidis
Polyneuropathy
Eidos Therapeutics, a BridgeBio companyP3B (60)
Adebrelimab
Hepatocellular Carcinoma
Third Affiliated Hospital, Sun Yat-Sen UniversityP3B (60)
Adebrelimab
Scurvy
Fudan UniversityP3B (60)
Adezunap
Vertebral Column Disorder
Apurano Pharmaceuticals GmbHP3B (60)
Adezunap
Diabetic Neuropathy
Apurano Pharmaceuticals GmbHP3B (60)
Adezunap
Diabetic Polyneuropathy
Apurano Pharmaceuticals GmbHP3B (60)
Adezunap
Peripheral Nervous System Disorder
Apurano Pharmaceuticals GmbHP3B (60)
Adriamycin
T-Cell Childhood Lymphoblastic Lymphoma
National Cancer Institute (NCI)P3B (60)
Adriamycin
Pediatric Hepatocellular Carcinoma
Children's Oncology GroupP3B (60)
Adriamycin
Hepatoblastoma
Children's Oncology GroupP3B (60)
Adriamycin
Fibrolamellar Hepatocellular Carcinoma
Children's Oncology GroupP3B (60)
Showing 2726 to 2750 of 5,098 assets
PreviousPage 110 of 204Next